Introduction
Inflammatory breast cancer (IBC) is a rare type of invasive breast cancer that occurs in only about 2-5% of all breast cancer cases. 1 However, it is one of the most aggressive forms of invasive breast cancer. It frequently presents with regional lymph node involvement and is followed by rapid disease progression to distant involvement from micrometastasis in the natural course of disease. With locoregional treatment only, long-term survival is less than 5%. 2 With the addition of systemic cytotoxic chemotherapy together with locoregional treatment, the long term survival has improved significantly but still resides between 30-50%. 2 IBC, being a chemo-sensitive disease, the standard main force of treatment is systemic cytotoxic chemotherapy. Compared to non-IBC, a previous study has found a survival hazard ratio (HR) of 1.43 for IBC using standard dose systemic cytotoxic chemotherapy. 3 One area of research in improving the IBC outcome was the potential use of high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHCT).
Multiple phase II studies of HDC with AHCT have been conducted in IBC which suggested a survival benefit in this aggressive locally advanced breast cancer compared to historical data of non-transplant approach. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In 1997, Antman et al. published the first report of HDC with AHCT for breast cancer in North America using data in the Autologous Blood and Marrow Transplant Registry (ABMTR). 17 Between January 1, 1989 and June 30, 1995, a total of 260 non-metastatic IBC patients receiving HDC with AHCT for breast cancer were reported to ABMTR. The 3-year Kaplan-Meier estimates of progression-free survival (PFS) were 42% (95% confidence interval [CI] of 31-53%) and the 3-year Kaplan-Meier estimates of overall survival (OS) were 52% (95% CI of 40-64%).
In 2003, Pedrazzoli et al. reported the data of European Group for Blood and Marrow Transplantation registry between 1990 and 1999. 18 A total of 921 patients with IBC underwent HDC with AHCT. Five years PFS was reported as 42% and 5 years OS was 53%.
However, these data were all reported decades ago. Therefore, it is worth studying the outcome of IBC patients and that of non-IBC patients who underwent HDC with AHCT again using the current global blood and marrow transplant registry data. Our primary objective was to compare the long-term outcomes of HDC with AHCT in IBC with that of non-IBC patients receiving HDC with AHCT.
Methods
The Center for International Blood & Marrow Transplant Research (CIBMTR), is a research affiliation of the International Bone Marrow Transplant Registry (IBMTR), ABMTR, and the National Marrow Donor Program (NMDP). The CIBMTR comprises a voluntary working group of more than 450 transplantation centers worldwide that contribute detailed data on consecutive allogeneic and autologous hematopoietic cell transplantation to a Statistical Center at the Medical College of Wisconsin in Milwaukee and the NMDP Coordinating Center in Minneapolis. Participating centers are required to report all transplants consecutively. Patients are followed longitudinally. Computerized checks for discrepancies, physicians' review of submitted data, and on-site audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. Protected Health Information used in such research is collected and maintained in CIBMTR's capacity as a Public Health Authority under the HIPAA Privacy Rule.
Patients
All patients who underwent HDC with AHCT for IBC or non-IBC between 1990 and 2002 were eligible for the study. Since follow-up information regarding long-term survival and secondary malignancies was required, patients from centers with a follow-up completeness index (ratio of total observed to potential person-time of follow-up) of < 80% at 10 years after transplantation were excluded (n=2423, from 98 centers). The final study population consisted of 3387 patients from 91 centers. Pathology and physician reports of second cancers were reviewed centrally, and if necessary, tumors were reclassified.
Statistical Methods
The objectives of this study were to compare the long-term outcomes between the IBC and non-IBC cohorts. The primary outcomes were PFS and OS. Secondary outcomes included disease relapse/progression, transplant related mortality (TRM) and cumulative incidence of secondary malignancy. Tables of patient-, disease-, treatmentand transplant-related characteristics were described using standard techniques. Continuous variables were reported as medians with ranges, while categorical variables were reported as absolute numbers and percent of total patients. The diagnosis of IBC is based on criteria described in AJCC cancer staging manual and the stage is at least stage IIIB. When the breast cancer presented de novo with distant metastasis, it was recorded as stage IV. TRM was defined as death in continued remission; patients were censored at relapse/progression, or for those in continuous remission, at last follow-up. For PFS, patients were considered treatment failures at the time of relapse or disease progression or death from any cause; patients alive were censored at the last follow-up evaluation. TRM, relapse/disease progression and secondary malignancy were estimated as cumulative incidences, taking into account competing risks. Probability of PFS was calculated using the Kaplan-Meier estimator with variance estimated by the Greenwood formula. Comparison of survival curves was done using the log-rank test. In multivariate analysis, a stepwise selection procedure was performed using the proportional hazards model.
Results

Patient Characteristics
Our study population included 527 patients with IBC and 2,860 patients with non-IBC ( Table 1 ). Among them, 442 patients (84%) with IBC had no de novo distant metastatic disease (stage III) and 2,302 patients (80%) with non-IBC had high risk stage II/III disease at initial presentation. The median age at transplantation (47 vs 46 years old) and median follow-up period in the 2 groups (167 vs 168 months) were similar. About half of the patients were premenopausal (53% vs 50%). Majority (84% vs 80% in IBC and non-IBC groups, respectively) had a good performance status (KPS > 90%) at transplant. At the time of transplantation, 346 patients (66%) with IBC and 1,425 patients (50%) with non-IBC had no evidence of active disease. Among the 85 patients (16%) with IBC and 558 patients (20%) with non-IBC who had stage IV disease, a majority of them had only one metastatic site (49 in IBC and 324 in non-IBC) with skin (other than the ipsilateral breast) being the most common metastatic site in IBC and bone in non-IBC. One hundred eighty-six patients (35%) with IBC and 830 patients (29%) with non-IBC were hormone receptor negative. HER2 receptor information was not available. Three hundred and four patients (58%) with IBC and 293 patients (10%) with non-IBC received neoadjuvant chemotherapy but only 55 and 64 patients respectively had complete response to neoadjuvant treatment. Majority of patients had surgery (90% vs 95%) and adjuvant chemotherapy (60% vs 67%) as part of their initial treatment before transplant. Single AHCT (versus tandem AHCT) was the common strategy in both groups (93%). The most commonly used conditioning regimen was cyclophosphamide, carboplatin, and others in both groups (54% in IBC and 50% in non-IBC). Majority used peripheral blood cells as the graft source (91% vs 88%). Median time from diagnosis to transplant was also similar in 2 groups (7 months in IBC and 10 months in non-IBC). With median follow up of 14 years, 10 patients in IBC and 42 patients in non-IBC developed second malignancy (Table 1 ). Overall, the cumulative incidence of a second primary malignancy in the entire cohort at 10 years post-transplant was 3% (95% CI: 2 to 4%) with 3% in the IBC group (95% CI: 2 to 4%) versus 2% (95% CI: 0 to 5%) in the non-IBC group. The most common cause of death was disease progression (81% in IBC and 75% in non-IBC) ( Table  2 ). 
Outcomes
In univariate analysis the cumulative incidence of TRM at 1 year was 2% (95% CI:1-4%) for IBC and 3% (95% CI:3-4%) for non-IBC (p=0.16) ( Table 3 ). The cumulative incidence of relapse/progression at 1 year was 39% (95% CI:35-43%) for IBC and 38% (95% CI:36-40%) for non-IBC (p=0.79), but at 10 years was 67% (95% CI:63-71%) for IBC and 69% (95% CI:68-71%) for non-IBC (p=0.36). The median survival for IBC was 40 months which was the same as that of the non-IBC. The probability of PFS at 1 year was 59% (95% CI:54-63%) for IBC and 58% (95% CI:57-60%) for non-IBC (p=0.86), but at 10 years was 27% (95% CI: 23-31%) for IBC and 24% (95% CI: 22-26%) for non-IBC (p=0.21), and the probability of OS at 1 year was 82% (95% CI:79-85%) for IBC and 80% (95% CI:79-82%) for non-IBC (p=0.41), but at 10 years was 31% (95% CI: 27-35%) for IBC and 28% (95% CI: 26-30%) for non-IBC (p=0. 16) .
No difference was seen in TRM, 1-year and 10-year relapse/progression, 1-year and 10-year PFS, and 1-year and 10-year OS between stage III IBC (n=442) and stage II/III non-IBC (n=2,302) ( Table 3) . No difference was also seen in TRM, relapse/progression, PFS and OS between IBC (n=346) and non-IBC (n=1,425) patients who had no active disease at transplantation (Figure 1 and 2) . However, among the subgroup of patients with stage III IBC (n=304) or stage II/III non-IBC (n=417) at presentation and had no active disease at transplantation (Table 3) , an univariate analysis showed that the IBC patients had worse outcomes than did non-IBC patients in terms of 1-year relapse rate (26% vs 18%, p=0.01), 10-year relapse rate (60% vs 50%, p=0.01), 10-year PFS rate (34% vs 42%, p=0.05), and 10-year OS rate (37% vs 45%, p=0.03) (Figure 3) .
In multivariate analysis, controlling for age, disease status at AHCT, hormonal receptor status, time from diagnosis to AHCT, and Karnofsky performance score (KPS) at AHCT, amongst patients with stage III IBC had higher mortality (HR 1.16, 95% CI: 1-1.34, p= 0.0459), worse PFS (HR: 1.17, 95% CI: 1.01-1.36, p= 0.0339) and higher risk of disease relapse/progression (HR: 1.24, 95% CI: 1.06-1.45, p= 0.0082) as compared to non-IBC (Tables 4) . Amongst all patients a higher stage disease was associated with worse survival outcomes (PFS and OS).
Discussion
Our study showed that on univariate analysis, the short term (1-year) and long term (10-year) outcomes of HDC with AHCT in IBC were similar to that in non-IBC. These similar results were also shown between stage III IBC and stage II/III non-IBC as well as between IBC and non-IBC with no active disease at transplantation. However, among the subgroup of stage III patients with no active disease at transplantation who were the "ideal" breast cancer patients for HDC with AHCT, the IBC patients had similar short term (1-year) outcomes but poorer long term (10-year) outcomes than that of non-IBC patients. Multivariate analysis also revealed that the stage III IBC patients regardless of the disease status at transplantation had poorer outcomes than did stage III non-IBC patients with a slightly inferior survival (hazard ratio for death = 1.16) to that reported previously (HR=1.43) in non-transplant setting. 3 Therefore the long term outcome of patients with IBC remained poor compared to that of patients with non-IBC even in the setting of transplantation. Our study is unique in terms of the numbers of patients and the duration of follow up. In the setting of HDC with AHCT the current analysis represents one of the largest numbers of breast cancer patients (more than 3,000 IBC and non-IBC patients together) and the longest follow up (more than 10 years). Given the long follow up, the nature of registry data and loss of interest in transplant treatment modality for breast cancer, there are limitations. With the concern of missing or unknown data, we also looked at 1-year short term outcomes since patients underwent HDC with AHCT would have had more complete follow up within the first year post-transplant. Similarly, data that are routinely obtained such as the HER2 receptor information were not collected in the era during which these transplants were performed. Since patients were contributed by numerous different transplant centers in the world, standard treatments given to the patient before transplant varied. Only 58% of patients with IBC and 10% of patients with non-IBC received neoadjuvant chemotherapy which was much less than the current standard of care for patients with IBC and for patients with locally advanced non-IBC. Nevertheless, our study suggests similar overall poor outcome of IBC patients who underwent HDC with AHCT compared with that of non-IBC patients. For stage III patients who underwent HDC with AHCT in the absence of active disease at transplant, our study confirmed the similar short term and the worse long term outcomes of IBC patients compared with non-IBC. The smaller HR for mortality of 1.16 compared to the previously reported HR of 1.43 in non-transplant setting may suggest that the potential benefit of HDC with AHCT is in short term disease control but not in long term disease eradication.
With 14 years of median follow up, the incidence of second primary malignancy was low, with the caveat of incomplete follow up mentioned earlier (2,423 patients were excluded due to < 80% follow-up completeness index at 10 years). In both groups, the chance of developing secondary malignancy after HDC was less than 3%. The TRM from the transplant procedure was low at 2 and 3% in both the groups and the TRM from the second malignancy was also very low in both groups (1% each). None of the second malignancy was breast cancer. We are thereby able to conclude that the procedure of HDC with AHCT in breast cancer patients has very low risk of treatment-related mortality.
The role of HDC with AHCT in invasive breast cancer has long been debated. Since the late 1990s, a total of 15 randomized phase III trials of HDC with AHCT in high-risk primary breast cancer [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and 8 randomized phase III trials in metastatic breast cancer [34] [35] [36] [37] [38] [39] [40] [41] have been described. In 2011, Berry et al. reported the first meta-analysis using individual data from all 15 trials in high-risk primary breast cancer 42 and 6 of the 8 trials in metastatic breast cancer. 43 In high-risk primary breast cancer setting, the analysis showed a significant benefit of HDC with AHCT in relapse-free survival with a HR of 0.87 (p < 0.001) but not in OS (HR of 0.94, p = 0.13). In metastatic breast cancer setting, the analysis showed a significant benefit in PFS with a HR of 0.76 (p < 0.001) but not in OS (HR of 0.89, p = 0.13). These findings also suggest that the potential benefit of HDC with AHCT is in slowing down the progression of disease. Subgroup analysis in both settings failed to show a benefit in any particular subpopulation. However, with the rarity of IBC, not many cases were included in the above randomized phase III trials. Some of the IBC cases were included in the locally advanced breast cancer group including non-inflammatory stage III breast cancer during the survival analysis. Therefore those randomized phase III trials did not particularly address the role of HDC with AHCT in IBC.
There has only been one randomized phase III study for patients with IBC who underwent HDC with AHST, which was the PEGASE 07 trial. 44 However this trial did not evaluate the impact of transplant in IBC, but instead, it studied the use of adjuvant chemotherapy after AHCT in IBC. In this trial, all patients received 4 cycles of high-dose cyclophosphamide and epirubicin with the hematopoietic cells collected after the cycle 1 and re-infused after cycle 2, 3 and 4 upon enrollment. Then patients proceeded to locoregional therapy of primary surgery and radiation therapy. After the locoregional therapy, patients were randomized to either observation with no chemotherapy or another 4 cycles of adjuvant chemotherapy of docetaxel and 5-fluorouracil. The primary endpoint was disease-free survival. With a median follow up of 60 months and a total of 174 patients (87 in each arm), the 5-year disease-free survival for patients received no adjuvant chemotherapy and received adjuvant chemotherapy were 55% and 55.5% respectively (HR of 0.94, p = 0.81). The 5-year OS for patients received no adjuvant chemotherapy and received adjuvant chemotherapy were 70.2% and 70% respectively (HR of 0.93, p = 0.81). 45 Since the introduction of multidisciplinary approach especially the use of systemic cytotoxic chemotherapy as early as possible in the course of IBC management, there has not been any other major breakthrough in the treatment of IBC except in HER2 positive IBC. IBC is more likely to be HER2 positive than non-IBC. Literatures suggested about 35% of IBC overexpressed HER2. 46, 47 The more favorable outcome of HER2 positive IBC is attributed to the effective therapy with adding trastuzumab to the chemotherapy. However, the outcome of HER2 negative IBC remains poor. Our study cannot support the use of HDC with AHCT in IBC outside of context of a clinical trial. IBC remains as one of the invasive breast cancers with poor prognosis. Pre-clinical research and well-designed clinical trials are needed to test the efficacy of new treatment modalities in IBC based on the pathobiology of the disease.
